TRANSDERMAL NICOTINE TREATMENT OF MCI

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项为期12个月的三个地点的初步临床试验，旨在评估经皮尼古丁缓解轻度认知障碍（MCI）症状的安全性和有效性。 试验将包括6个月的尼古丁或安慰剂随机双盲安慰剂对照治疗，随后6个月的开放标签尼古丁治疗。 本试验的主要目的是确定长期尼古丁在非吸烟老年患者中的安全性，次要目的是检查尼古丁是否会缓解MCI的认知症状，以及患者和临床医生是否可以检测到这种作用。 虽然这项试验的规模不够大，时间不够长，无法获得尼古丁对认知障碍进展为阿尔茨海默病的影响的数据，但我们希望这项试验的结果将证明有足够的时间进行更大规模的多中心试验，以充分研究这个问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a three-site 12-month pilot clinical trial of the safety and efficacy of transdermal nicotine in alleviating symptoms of Mild Cognitive Impairment (MCI). The trial will consist of 6 months of randomized double-blind placebo-controlled treatment with nicotine or placebo followed by 6 months of open label nicotine treatment. The primary goal of this trial will be to establish the safety of long-term nicotine in non-smoking older patients with a secondary goal of examining whether nicotine will alleviate cognitive symptoms of MCI and whether this effect will be detectable by patients and clinicians. While this trial will not be sufficiently large enough or long enough to obtain data on the effects of nicotine on the progression of cognitive impairment to Alzheimer's disease, we hope that the results of this trial will justify a larger multi-center trial of sufficient duration to fully examine this question.